Neoadjuvant Therapy in Pancreatic Cancer: An Emerging Strategy

Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design

(2013) Matthew H. G. Katz et al.   ANNALS OF SURGICAL ONCOLOGY

A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer

(2013) Edward J. Kim et al.   CANCER

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma

(2012) Peter J Hosein et al.   BMC CANCER

FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity

(2012) Krishna S. Gunturu et al.   MEDICAL ONCOLOGY

Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma

(2012) Jae-Lyun Lee et al.   SURGERY

Advanced age is a risk factor for post-operative complications and mortality after a pancreaticoduodenectomy: a meta-analysis and systematic review

(2012) Sukharamwala Prashant et al.   HPB

Preoperative Capecitabine and Concurrent Radiation for Borderline Resectable Pancreatic Cancer

(2011) Jayme B. Stokes et al.   ANNALS OF SURGICAL ONCOLOGY

Neoadjuvant GTX Chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer

(2011) Manish Patel et al.   JOURNAL OF SURGICAL ONCOLOGY

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: A meta-analysis

(2011) Chang-Peng Zhu et al.   RADIOTHERAPY AND ONCOLOGY

Pancreatic Cancer

(2010) Manuel Hidalgo   NEW ENGLAND JOURNAL OF MEDICINE

NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer

(2010) Klaus Sahora et al.   SURGERY

Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages

(2010) Sonja Gillen et al.   PLOS MEDICINE

Resectable Pancreatic Cancer: Who Really Benefits From Resection?

(2009) Giuliano Barugola et al.   ANNALS OF SURGICAL ONCOLOGY

A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer

(2009) H Ueno et al.   BRITISH JOURNAL OF CANCER

Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma

(2009) Michele Reni et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Margin Clearance and Outcome in Resected Pancreatic Cancer

(2009) David K. Chang et al.   JOURNAL OF CLINICAL ONCOLOGY

Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head

(2008) Gauri R. Varadhachary et al.   JOURNAL OF CLINICAL ONCOLOGY

Prospective Phase II Trial of Neoadjuvant Chemotherapy With Gemcitabine and Cisplatin for Resectable Adenocarcinoma of the Pancreatic Head

(2008) Stefan Heinrich et al.   JOURNAL OF CLINICAL ONCOLOGY

Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head

(2008) Douglas B. Evans et al.   JOURNAL OF CLINICAL ONCOLOGY

Borderline Resectable Pancreatic Cancer: The Importance of This Emerging Stage of Disease

(2008) Matthew H.G. Katz et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS